INVEST Pitch Perfect winner spotlight: Pleiogenix eyes road ahead for liver disease drug

acute alcoholic hepatitis, BioPharma, biopharma nl, California, carlsbad, COVID-19, Daily, invest 2020 virtual, nonalcoholic steatohepatitis, Pleiogenix, PLX888, SYN, Top Story / August 3, 2020

The company is hoping to close its seed funding round in the next six months and aims to be in a position to seek regulatory approval for its lead asset, PLX888, in acute alcoholic hepatitis in 2023.